UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2015
Insys Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-35902 | | 51-0327886 |
(State or other jurisdiction of incorporation) | | (Commission File No.) | | (IRS Employer Identification No.) |
1333 S. Spectrum Blvd, Suite 100
Chandler, Arizona 85286
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (602) 910-2617
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2015, Insys Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2015. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On November 3, 2015, the Board of Directors of the Company adopted a new stock repurchase program. The stock repurchase program authorizes up to $50 million in repurchases of common stock in the open market, block transactions on or off an exchange, or in privately negotiated transactions at management's discretion from time to time. The stock repurchase program is effective immediately, and there is no fixed termination date for this program. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be retired as repurchased.
A press release announcing the repurchase program was issued on November 5, 2015 and is attached hereto as Exhibit 99.2 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
| |
99.1 | | Press Release dated November 5, 2015 Announcing Financial Results for Third Quarter |
99.2 | | Press Release dated November 5, 2015 Announcing Stock Repurchase Program |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
Date: November 5, 2015 | | Insys Therapeutics, Inc. |
| | |
| | By: | /s/ Darryl S. Baker | |
| | | Darryl S. Baker | |
| | | Chief Financial Officer | |
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
| |
99.1 | | Press Release dated November 5, 2015 Announcing Financial Results for Third Quarter |
99.2 | | Press Release dated November 5, 2015 Announcing Stock Repurchase Program |
